Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
10.83 MXN
−4.78 B MXN
987.15 M MXN
93.63 M
About CureVac N.V.
Sector
CEO
Alexander Zehnder
Headquarters
Tübingen
Website
Founded
2020
ISIN
NL0015436031
FIGI
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CVAC/N is 85.00 MXN — it has increased by 18.06% in the past 24 hours. Watch CUREVAC N.V stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange CUREVAC N.V stocks are traded under the ticker CVAC/N.
We've gathered analysts' opinions on CUREVAC N.V future price: according to them, CVAC/N price has a max estimate of 324.44 MXN and a min estimate of 50.96 MXN. Watch CVAC/N chart and read a more detailed CUREVAC N.V stock forecast: see what analysts think of CUREVAC N.V and suggest that you do with its stocks.
CVAC/N stock is 18.22% volatile and has beta coefficient of 1.31. Track CUREVAC N.V stock price on the chart and check out the list of the most volatile stocks — is CUREVAC N.V there?
Today CUREVAC N.V has the market capitalization of 11.61 B, it has increased by 35.53% over the last week.
Yes, you can track CUREVAC N.V financials in yearly and quarterly reports right on TradingView.
CUREVAC N.V is going to release the next earnings report on Apr 23, 2025. Keep track of upcoming events with our Earnings Calendar.
CVAC/N earnings for the last quarter are 32.91 MXN per share, whereas the estimation was 30.93 MXN resulting in a 6.38% surprise. The estimated earnings for the next quarter are −5.26 MXN per share. See more details about CUREVAC N.V earnings.
CUREVAC N.V revenue for the last quarter amounts to 220.59 M MXN, despite the estimated figure of 73.53 M MXN. In the next quarter, revenue is expected to reach 191.24 M MXN.
CVAC/N net income for the last quarter is 7.32 B MXN, while the quarter before that showed −1.43 B MXN of net income which accounts for 610.82% change. Track more CUREVAC N.V financial stats to get the full picture.
No, CVAC/N doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 18, 2024, the company has 1.17 K employees. See our rating of the largest employees — is CUREVAC N.V on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CUREVAC N.V EBITDA is 4.06 B MXN, and current EBITDA margin is −473.93%. See more stats in CUREVAC N.V financial statements.
Like other stocks, CVAC/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CUREVAC N.V stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CUREVAC N.V technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CUREVAC N.V stock shows the strong sell signal. See more of CUREVAC N.V technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.